| Ba, Yi |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04555304: Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy |
|
|
| Not yet recruiting | 2 | 81 | NA | KH903 + Paclitaxel, Placebo + Paclitaxel | Chengdu Kanghong Biotech Co., Ltd. | Gastric Cancer, Gastroesophageal Cancer | 01/22 | 01/22 | | |
NCT05035381: PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin | Tianjin Medical University Cancer Institute and Hospital | MSI-H Advanced Colorectal Cancer | 12/22 | 12/22 | | |
NCT04969029: Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations |
|
|
| Recruiting | 2 | 30 | RoW | Tirelizumab | Tianjin Medical University Cancer Institute and Hospital | Immunotherapy, Adjuvant Therapy, Colon Cancer, MSI-H | 12/23 | 12/24 | | |
NCT06383559: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients |
|
|
| Recruiting | 2 | 39 | RoW | Lenvatinib and Sintilimab | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 07/26 | 09/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06430827: Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma |
|
|
| Not yet recruiting | 2 | 20 | RoW | irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin | Ba Yi, CSPC Ouyi Pharmaceutical Co., Ltd. | Biliary Tract Carcinoma | 12/24 | 12/25 | | |
TOBACO, NCT05077839: Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC |
|
|
| Recruiting | 2 | 184 | RoW | Trifluridine/Tipiracil, TAS-102 | Tianjin Medical University Cancer Institute and Hospital | First-line Treatment, Advanced Colorectal Cancer | 08/24 | 08/25 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC |
|
|
| Not yet recruiting | 1 | 60 | NA | SCT-I10A, SCT200, Chemotherapy | Sinocelltech Ltd. | Esophageal Squamous Cell Carcinoma, Colorectal Cancer | 08/22 | 12/22 | | |
NCT05388279: A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors |
|
|
| Terminated | 1 | 3 | RoW | JS012, JS012 combine with chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Advanced or Metastatic Solid Tumors | 09/22 | 09/22 | | |
NCT04190823: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 63 | RoW | RC98, RC98 for Injection | RemeGen Co., Ltd. | Solid Tumors | 12/23 | 12/23 | | |
| Recruiting | 1 | 96 | RoW | TQB3454 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/22 | 12/22 | | |
NCT05221775: Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients |
|
|
| Recruiting | 1 | 18 | RoW | Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | First-line Treatment, Advanced Gastric Carcinoma | 03/23 | 10/23 | | |
NCT05514158: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) |
|
|
| Recruiting | 1 | 24 | RoW | RC48-ADC, RC48-ADC injection, RC98, RC98 injection | RemeGen Co., Ltd. | Gastric Cancer | 05/24 | 09/24 | | |
NCT05367635: A Study of SKB315 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 206 | RoW | SKB315 for injection | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 05/24 | 05/24 | | |
| Not yet recruiting | 1 | 96 | RoW | KM501 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/26 | 12/27 | | |
